№ files_lp_4_process_1_37617
File format: docx Character count: 27205 File size: 498 KB
The document analyzes the actual versus predicted utilization of single inhaler triple therapies for severe asthma in Australia, assessing the cost to the government and potential deviations from the prescribed usage restrictions.
Year: 2025
Region / city: Australia
Topic: Severe asthma treatment and medication analysis
Document type: Report
Organization: Drug Utilisation Sub-committee (DUSC)
Author: Unknown
Target audience: Healthcare professionals, policymakers
Period of validity: April 2025
Date of approval: Not mentioned
Date of changes: Not mentioned
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Fluticasone Furoate with Umeclidinium and Vilanterol, Powder for Oral Inhalation in Breath Actuated Device
Year: 2021
Region / City: Australia
Subject: Chronic Obstructive Pulmonary Disease (COPD)
Document Type: Application for PBS Listing Amendment
Organization: GlaxoSmithKline
Author: Not specified
Target Audience: Medical Practitioners, Healthcare Professionals
Period of Effect: Not specified
Approval Date: Not specified
Modification Date: Not specified
Requested Action: Removal of clinical criteria in PBS listing for Trelegy
Clinical Focus: Treatment of moderate to severe COPD
Intervention: Trelegy inhalation therapy (ICS/LAMA/LABA combination)
Comparator: Dual therapy LAMA/LABA
Outcomes: Reduction in COPD exacerbations, improvement in lung function
Indication: Chronic Obstructive Pulmonary Disease (COPD)
Restriction: Authority required, restricted benefit
Administrative Notes: Emphasis on correct inhaler technique, spirometry requirement for COPD diagnosis
Fluticasone Furoate with Umeclidinium and Vilanterol, Powder for Oral Inhalation in Breath Actuated Device
Year: 2021
Region / City: Australia
Subject: Chronic Obstructive Pulmonary Disease (COPD)
Document Type: Application for PBS Listing Amendment
Organization: GlaxoSmithKline
Author: Not specified
Target Audience: Medical Practitioners, Healthcare Professionals
Period of Effect: Not specified
Approval Date: Not specified
Modification Date: Not specified
Requested Action: Removal of clinical criteria in PBS listing for Trelegy
Clinical Focus: Treatment of moderate to severe COPD
Intervention: Trelegy inhalation therapy (ICS/LAMA/LABA combination)
Comparator: Dual therapy LAMA/LABA
Outcomes: Reduction in COPD exacerbations, improvement in lung function
Indication: Chronic Obstructive Pulmonary Disease (COPD)
Restriction: Authority required, restricted benefit
Administrative Notes: Emphasis on correct inhaler technique, spirometry requirement for COPD diagnosis
Investigation of the Relaxation Effect of Fluticasone Furoate Blends within Ellipta® Device
Authors: Karin Marek; Maribel Bogalo Huescar; Andre Widmann; Anna Lachenmaier; Ali Verdi; Judith Schwab; Birsen Öztürk; Andrea Silvestri; Irene Rossi
Affiliations: Harro Höfliger, Allmersbach im Tal, Germany; DFE Pharma, Goch, Germany; Sterling, Corciano, Italy
Countries: Germany; Netherlands; Italy; United Kingdom; Switzerland
Topic: Dry powder inhalers; fluticasone furoate; blend relaxation; high shear mixing; lactose-based formulations
Document Type: Scientific research article
Study Focus: Relaxation effect of fluticasone furoate blends during ambient storage
Materials: Fluticasone furoate; lactose; vilanterol trifenatate; magnesium stearate
Device: Ellipta® inhaler
Methods: High shear mixing; particle size analysis; SEM; solution calorimetry; BET; NGI; HPLC
Storage Conditions: Ambient conditions
Testing Intervals: After manufacturing and every two weeks of storage
Related Product: Relvar® Ellipta generic development
Fluticasone Furoate with Umeclidinium and Vilanterol, Powder for Oral Inhalation in Breath Actuated Device
Year: 2021
Region / City: Australia
Subject: Chronic Obstructive Pulmonary Disease (COPD)
Document Type: Application for PBS Listing Amendment
Organization: GlaxoSmithKline
Author: Not specified
Target Audience: Medical Practitioners, Healthcare Professionals
Period of Effect: Not specified
Approval Date: Not specified
Modification Date: Not specified
Requested Action: Removal of clinical criteria in PBS listing for Trelegy
Clinical Focus: Treatment of moderate to severe COPD
Intervention: Trelegy inhalation therapy (ICS/LAMA/LABA combination)
Comparator: Dual therapy LAMA/LABA
Outcomes: Reduction in COPD exacerbations, improvement in lung function
Indication: Chronic Obstructive Pulmonary Disease (COPD)
Restriction: Authority required, restricted benefit
Administrative Notes: Emphasis on correct inhaler technique, spirometry requirement for COPD diagnosis
Topics: Umeclidinium Vilanterol Fluticasone